Takeda signs Omontys injection supply contract with Fresenius

Takeda Pharmaceuticals America (TPA) has signed a contract to supply Omontys injection to Fresenius Medical Care North America and certain of its affiliates.

Omontys (peginesatide) injection is a synthetic, pegylated, peptide-based erythropoiesis-stimulating agent (ESA) indicated to treat anemia in patients with chronic kidney disease (CKD).

According to the agreement, which ends in April 2013, Fresenius Medical Care North America can purchase Omontys for use in US centers within its organization and provides for discounts and rebates on the product, subject to certain requirements. Financial terms of the agreement were kept confidential.

Takeda marketing vice president Nicole Mowad-Nassar said, “We are excited to partner with Fresenius Medical Care North America, one of the world’s leading dialysis providers, to offer a new therapeutic option for the treatment of anemia in its chronic kidney disease patients on dialysis.”

Fresenius Medical Care North America plans to adopt the product into more than 100 dialysis centers in the US over the next few weeks initially, and then, based on its experience, evaluate the potential to expand to additional centers.